Management of advanced prostate cancer

Revista da Associacao Medica Brasileira

Volumn 54, Issue 2, 2008, Pages 178-182

  Kaliks, Rafael A ^a,b   Del Giglio, Auro ^a  

^a ABC School of Medicine   (Brazil)

^b NONE   (Brazil)

Author keywords

Drug therapy; Epidemiology; Hormonal antineoplastic agents; Hormones therapeutic use; Prostatic neoplasms therapy

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BRAZIL; HEALTH CARE DELIVERY; HUMAN; MALE; METASTASIS; PROSTATE TUMOR; REVIEW;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRAZIL; DELIVERY OF HEALTH CARE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 45849097572     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302008000200025     Document Type: Review

References (22)

1. Di Blasio CJ, Rhee AC, Cho D, Scardino PT, Kattan MW. Predicting clinical end points: treatment nomograms in prostate cancer. Semin Oncol. 2003;30(5):567-86.
2. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstenin JI, Pearson JD. Contemporary update of prostate cancer nomograms (Partin tables) for the new millennium. Urology. 2001;58(8):843.
3. Wilt T, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev. 2002;(1):CD003506.
4. Schröder FH, Kurth KH, Fosså SD, Hoekstra W, Karthaus PP, Debois M, et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846 - a phase III study. J Urol. 2004;172(3):923-7.
5. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341(24):1781-8.
6. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nature Rev Cancer. 2001;1(1):34-45.
7. Studer UE, Whelan P, Albrecht W, Casselman J, De Reijke T, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24(18):1868-76.
8. Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology. 2001;58(2):240-5.
9. De La Taille A, Zerbib M, Conquy S, Amsellem-Ouazana D, Thiounn N, Flam TA, et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int. 2003;91(1):18-22.
10. Bhandari MS, Crook J, Hussain M. Should intermittent Androgen deprivation be used in routine clinical practice. J Clin Oncol. 2005;23(32):8212-8.
11. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000;355(9214):1491-8.
12. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev. 2000;(2):CD001526.
13. Schroder FH. Cyproterone acetate-mechanism of action and clinical effectiveness in prostate cancer treatment. Cancer.1993;72(12):3810-15.
14. Schroder FH, Whelan P, De Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, et al. Members of the EORTC Genito-Urinary Group, "Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the 'European Organization for Research and Treatment of Cancer' (EORTC) Protocol 30892". Eur Urol. 2004;45(4):457-64.
15. Trump DL, Havlin KH, Messing EM, Cummings KB, Lange PH, Jordan VC. High-dose ketoconazole in advanced hormone-refractoryprostate cancer: endocrinologic and clinical effects by. J Clin Oncol. 1989;7(8):1093-8.
16. Small EJ, Halabi S, Dawson NA, Rini BI, Picus J, Gable P, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III Trial (CALGB 9583) J Clin Oncol. 2004;22(6):1025-33.
17. Tannock IF, Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Eng J Med. 2004;351(15):1502-12.
18. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-20.
19. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol. 2005;23(32):8247-52.
20. Small EJ, Smith MR, Seaman JJ, Petrone K, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21(23):4277-84.
21. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-68.
22. Michaelson MD, Lee H, Kaufman DS, Annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized placebo-controlled trial. J Clin Oncol. 2006;24(18S):4515.